JP6256772B2 - ヒストンデメチラーゼ阻害剤 - Google Patents
ヒストンデメチラーゼ阻害剤 Download PDFInfo
- Publication number
- JP6256772B2 JP6256772B2 JP2015549728A JP2015549728A JP6256772B2 JP 6256772 B2 JP6256772 B2 JP 6256772B2 JP 2015549728 A JP2015549728 A JP 2015549728A JP 2015549728 A JP2015549728 A JP 2015549728A JP 6256772 B2 JP6256772 B2 JP 6256772B2
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- compound
- fluoro
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- MDHZNBDRDJQKNA-UHFFFAOYSA-N CC(C)(C)OC(N1CC(CC[n](c(c2c3)ccc3F)nc2I)CCC1)=O Chemical compound CC(C)(C)OC(N1CC(CC[n](c(c2c3)ccc3F)nc2I)CCC1)=O MDHZNBDRDJQKNA-UHFFFAOYSA-N 0.000 description 1
- VWIMPFAZHUNPKK-UHFFFAOYSA-N CCC[n](c1c2CCC=C1F)nc2Nc(cncc1)c1C(O)=O Chemical compound CCC[n](c1c2CCC=C1F)nc2Nc(cncc1)c1C(O)=O VWIMPFAZHUNPKK-UHFFFAOYSA-N 0.000 description 1
- JITWKGJFUDNUKH-UHFFFAOYSA-N CN1CCC(CC[n](c(cc2)c3cc2F)nc3Nc(cncc2)c2C(O)=O)CC1 Chemical compound CN1CCC(CC[n](c(cc2)c3cc2F)nc3Nc(cncc2)c2C(O)=O)CC1 JITWKGJFUDNUKH-UHFFFAOYSA-N 0.000 description 1
- QWHULRZVRSTPNH-UHFFFAOYSA-N CNCCCCC[n](c(cc1)c2cc1F)nc2Nc(cncc1)c1C(O)=O Chemical compound CNCCCCC[n](c(cc1)c2cc1F)nc2Nc(cncc1)c1C(O)=O QWHULRZVRSTPNH-UHFFFAOYSA-N 0.000 description 1
- NMKOEUOMKQUPGP-UHFFFAOYSA-N Fc(cc1)cc2c1[n](CC1OCCC1)nc2I Chemical compound Fc(cc1)cc2c1[n](CC1OCCC1)nc2I NMKOEUOMKQUPGP-UHFFFAOYSA-N 0.000 description 1
- GRCMLULLNYVGSI-UHFFFAOYSA-N Fc(ccc1n[n]2CC3OCCC3)cc1c2I Chemical compound Fc(ccc1n[n]2CC3OCCC3)cc1c2I GRCMLULLNYVGSI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739521P | 2012-12-19 | 2012-12-19 | |
| US61/739,521 | 2012-12-19 | ||
| US201361792930P | 2013-03-15 | 2013-03-15 | |
| US61/792,930 | 2013-03-15 | ||
| PCT/US2013/076666 WO2014100463A1 (en) | 2012-12-19 | 2013-12-19 | Histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503799A JP2016503799A (ja) | 2016-02-08 |
| JP2016503799A5 JP2016503799A5 (show.php) | 2016-12-01 |
| JP6256772B2 true JP6256772B2 (ja) | 2018-01-10 |
Family
ID=50931614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549728A Expired - Fee Related JP6256772B2 (ja) | 2012-12-19 | 2013-12-19 | ヒストンデメチラーゼ阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US8969343B2 (show.php) |
| EP (1) | EP2934145B1 (show.php) |
| JP (1) | JP6256772B2 (show.php) |
| AU (1) | AU2013361255B2 (show.php) |
| CA (1) | CA2895355A1 (show.php) |
| CY (1) | CY1119901T1 (show.php) |
| DK (1) | DK2934145T3 (show.php) |
| ES (1) | ES2658597T3 (show.php) |
| HR (1) | HRP20180067T1 (show.php) |
| HU (1) | HUE037312T2 (show.php) |
| LT (1) | LT2934145T (show.php) |
| PL (1) | PL2934145T3 (show.php) |
| PT (1) | PT2934145T (show.php) |
| RS (1) | RS56821B1 (show.php) |
| SI (1) | SI2934145T1 (show.php) |
| SM (1) | SMT201800070T1 (show.php) |
| WO (1) | WO2014100463A1 (show.php) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10208043B2 (en) | 2012-08-22 | 2019-02-19 | Cornell University | Methods for inhibiting fascin |
| HRP20170358T1 (hr) | 2012-10-02 | 2017-04-21 | Gilead Sciences, Inc. | Inhibitori histonskih demetilaza |
| PL2934145T3 (pl) | 2012-12-19 | 2018-04-30 | Celgene Quanticel Research, Inc. | Inhibitory demetylazy histonowej |
| KR20150100814A (ko) | 2012-12-21 | 2015-09-02 | 콴티셀 파마슈티컬스, 인크. | 히스톤 데메틸라제 억제제 |
| ES2670864T3 (es) | 2013-02-27 | 2018-06-01 | Gilead Sciences, Inc. | Inhibidores de histonas desmetilasas |
| WO2014164708A1 (en) | 2013-03-12 | 2014-10-09 | Quanticel Pharmaceuticals, Inc. | Histone dementhylase inhibitors |
| EP2970307B1 (en) | 2013-03-13 | 2020-03-11 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| JP6691869B2 (ja) | 2014-02-20 | 2020-05-13 | コーネル ユニヴァーシティー | ファシンを阻害するための化合物及び方法 |
| US10385047B2 (en) | 2014-06-25 | 2019-08-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
| EP3194387B1 (en) | 2014-09-17 | 2019-07-31 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN107205391A (zh) | 2014-09-17 | 2017-09-26 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| JP6883913B2 (ja) * | 2015-12-28 | 2021-06-09 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| CN105601555B (zh) * | 2016-03-14 | 2018-07-31 | 苏州大学 | 一种制备硝基吲哚衍生物的方法 |
| WO2017161012A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CA3035346A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| EP3507288B1 (en) | 2016-09-02 | 2020-08-26 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| EP4234691A3 (en) | 2016-10-14 | 2023-10-18 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| EP3535242B1 (en) * | 2016-10-20 | 2024-01-24 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | Dna primase and gyrase inhibitors |
| AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| WO2018149986A1 (en) * | 2017-02-16 | 2018-08-23 | Oryzon Genomics, S.A. | 2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| NZ783169A (en) | 2019-06-25 | 2024-12-20 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| US20230303599A1 (en) | 2020-08-07 | 2023-09-28 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2023386923A1 (en) | 2022-11-21 | 2025-05-15 | Nippon Shinyaku Co., Ltd. | Compound serving as ddr1 kinase inhibitor, and medicine |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593349B2 (en) * | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| MXPA05001807A (es) * | 2002-09-05 | 2005-04-19 | Aventis Pharma Sa | Nuevos derivados de aminoindazol utilizados como medicamentos y composiciones farmaceuticas que los contienen. |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| FR2882361A1 (fr) * | 2005-02-22 | 2006-08-25 | Aventis Pharma Sa | Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation |
| AU2007275653B2 (en) * | 2006-07-20 | 2010-12-23 | Amgen Inc. | Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine |
| PH12013501594A1 (en) * | 2007-07-20 | 2014-05-12 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
| AU2009320683B2 (en) | 2008-11-28 | 2012-07-19 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| JP2014511389A (ja) | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換６，５−縮合二環式ヘテロアリール化合物 |
| PL2934145T3 (pl) | 2012-12-19 | 2018-04-30 | Celgene Quanticel Research, Inc. | Inhibitory demetylazy histonowej |
-
2013
- 2013-12-19 PL PL13866465T patent/PL2934145T3/pl unknown
- 2013-12-19 DK DK13866465.1T patent/DK2934145T3/en active
- 2013-12-19 US US14/134,989 patent/US8969343B2/en active Active
- 2013-12-19 HU HUE13866465A patent/HUE037312T2/hu unknown
- 2013-12-19 WO PCT/US2013/076666 patent/WO2014100463A1/en not_active Ceased
- 2013-12-19 AU AU2013361255A patent/AU2013361255B2/en not_active Ceased
- 2013-12-19 HR HRP20180067TT patent/HRP20180067T1/hr unknown
- 2013-12-19 SM SM20180070T patent/SMT201800070T1/it unknown
- 2013-12-19 CA CA2895355A patent/CA2895355A1/en not_active Abandoned
- 2013-12-19 US US14/653,818 patent/US9617242B2/en active Active
- 2013-12-19 JP JP2015549728A patent/JP6256772B2/ja not_active Expired - Fee Related
- 2013-12-19 SI SI201330913T patent/SI2934145T1/en unknown
- 2013-12-19 PT PT138664651T patent/PT2934145T/pt unknown
- 2013-12-19 RS RS20180071A patent/RS56821B1/sr unknown
- 2013-12-19 EP EP13866465.1A patent/EP2934145B1/en active Active
- 2013-12-19 ES ES13866465.1T patent/ES2658597T3/es active Active
- 2013-12-19 LT LTEP13866465.1T patent/LT2934145T/lt unknown
-
2017
- 2017-03-01 US US15/446,996 patent/US10040779B2/en active Active
-
2018
- 2018-02-09 CY CY20181100164T patent/CY1119901T1/el unknown
- 2018-06-29 US US16/024,452 patent/US10336727B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014100463A1 (en) | 2014-06-26 |
| RS56821B1 (sr) | 2018-04-30 |
| CA2895355A1 (en) | 2014-06-26 |
| SMT201800070T1 (it) | 2018-03-08 |
| EP2934145B1 (en) | 2017-11-15 |
| AU2013361255B2 (en) | 2017-01-05 |
| LT2934145T (lt) | 2018-02-26 |
| SI2934145T1 (en) | 2018-03-30 |
| EP2934145A1 (en) | 2015-10-28 |
| JP2016503799A (ja) | 2016-02-08 |
| HUE037312T2 (hu) | 2018-08-28 |
| PL2934145T3 (pl) | 2018-04-30 |
| US8969343B2 (en) | 2015-03-03 |
| ES2658597T3 (es) | 2018-03-12 |
| PT2934145T (pt) | 2018-02-13 |
| US10336727B2 (en) | 2019-07-02 |
| CY1119901T1 (el) | 2018-06-27 |
| US9617242B2 (en) | 2017-04-11 |
| EP2934145A4 (en) | 2016-06-29 |
| US20140171432A1 (en) | 2014-06-19 |
| AU2013361255A1 (en) | 2015-07-09 |
| US20180305336A1 (en) | 2018-10-25 |
| US10040779B2 (en) | 2018-08-07 |
| DK2934145T3 (en) | 2018-02-05 |
| HRP20180067T1 (hr) | 2018-02-23 |
| US20160060247A1 (en) | 2016-03-03 |
| US20170174656A1 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6256772B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| US11987560B2 (en) | Inhibitors of lysine specific demethylase-1 | |
| JP6663866B2 (ja) | リジン特異的なデメチラーゼ−１の阻害剤 | |
| JP6256771B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6276378B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6320506B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6525422B2 (ja) | リジン特異的なデメチラーゼ−１の阻害剤 | |
| JP6332654B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| CN106660987B (zh) | 赖氨酸特异性脱甲基酶-1的抑制剂 | |
| TW202124369A (zh) | 組織蛋白去甲基化酶抑制劑 | |
| KR20170048601A (ko) | 히스톤 탈메틸효소 억제제 | |
| JP2019508447A (ja) | ヒストンデメチラーゼ阻害剤 | |
| CN115551496A (zh) | Stat抑制性化合物和组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150721 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161012 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161019 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171017 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171101 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20171106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171122 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6256772 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |